查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848552

灰指甲治療市場按藥物類型、活性成分、劑型、分銷管道、治療場所、年齡層、性別和疾病嚴重程度分類－2025-2032年全球預測

Onychomycosis Treatment Market by Drug Type, Active Ingredient, Formulation, Distribution Channel, Treatment Setting, Age Group, Gender, Disease Severity - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，灰指甲治療市場規模將成長 43 億美元，複合年成長率為 9.40%。

主要市場統計數據
基準年 2024 20.9億美元
預計年份：2025年 22.9億美元
預測年份：2032年 43億美元
複合年成長率 (%) 9.40%

闡述甲癬的當代臨床和商業性格局，重點關注未滿足的需求、相關人員的動態以及不斷發展的治療途徑

由於人口老化、併發症增加以及患者對治療耐受性和便利性的期望不斷提高，灰指甲在臨床和商業性持續面臨挑戰。臨床醫師因甲癬的非典型表現和混合病因而面臨診斷難題，而患者往往因顧慮外觀或認為既往治療無效而延誤就醫，造成巨大的未滿足醫療需求。

近年來，治療方法的進步，包括更具標靶性的局部抗真菌藥物、口服藥物的創新以及雷射療法等輔助技術，正在豐富治療途徑，並為不同患者群體提供更多選擇。然而，在依從性、長期復發預防和真實世界療效方面，仍有數據空白。支付者和醫療服務提供者正逐漸採用以價值主導的決策標準，強調安全性、治療持續時間和病患報告結局的顯著改善。

此次聘用整合了臨床背景、相關人員和不斷變化的治療動態，同時為深入探索影響甲癬治療產品開發、開發策略和競爭定位的監管、經濟和競爭力量奠定了基礎。

治療創新、製劑改良和漸進式治療給藥方式如何重新定義足癬的治療選擇、依從性和商業化

隨著治療方法創新與患者期望和治療模式的轉變，甲癬的治療格局正在變革時期。治療方法正從單一藥物聯合治療轉向綜合治療方案，將外用藥物、口服藥物、器械輔助治療和支持性措施相結合，以提高療效和患者依從性。這種多維度的策略正在重新思考臨床醫生如何選擇輕度和重度甲癬的治療方法，以及製造商如何在臨床訊息中突出產品優勢。

同時，對製劑科學的投入正在提升滲透促進劑、新型載體系統和易用性方面的作用，從而解決長期存在的障礙，例如指甲滲透緩慢和治療週期過長。新的活性成分和製劑策略正在接受測試，旨在降低復發率並提高療效持久性，而安全性和藥物交互作用仍然是多重用藥族群（尤其是老年人）採用這些藥物的關鍵因素。

在醫療服務提供方面，數位化管道和遠端醫療服務正在重塑患者就醫和追蹤方式，從而實現早期療育和更有效的依從性監測。藥房模式也在適應這一轉變，除了傳統的醫院和零售管道外，線上藥局和居家照護管道也日益普及。這些變革性趨勢既為創造差異化的臨床價值帶來了機遇，也為市場准入帶來了挑戰，因此需要製定一個綜合性的商業化計劃，該計劃需兼顧監管細則、支付方期望以及以患者為中心的定位。

評估美國關稅對供應鏈、採購和採購的影響（截至2025年）

美國在2025年前實施的新關稅政策，正對皮膚科和抗真菌產品的供應鏈、籌資策略和定價動態產生連鎖反應。從國際市場購買活性原料藥、輔料和最終產品的製造商正在調整其採購佈局和合約條款，以降低進口關稅和海關相關時間風險。此類調整通常會導致供應計劃的改變，進而影響分銷點的產品供應和庫存緩衝。

短期應對措施包括將零件採購轉移到國內或低關稅地區，重新談判供應商合約以納入關稅分攤條款，以及有選擇地增加關鍵SKU的國內庫存。長期來看，企業正在評估近岸製造和本地化配方設施，以此作為應對關稅帶來的成本壓力的結構性措施。這些策略性投資可以降低貿易波動帶來的風險，但需要做出影響產品上市時間和利潤率結構的資本配置決策。

支付者和採購團隊也積極應對，收緊合約條款，強調基於價值的合作模式，並仔細審查醫療總成本。臨床負責人和採購部門可能傾向於選擇那些在安全性或依從性方面具有差異化優勢的療法，這些優勢足以支撐價格調整，以應對不斷上漲的供應成本。最終結果是，供應鏈的韌性、商業性靈活性以及清晰傳達價值提案的能力變得更加重要，這些價值主張能夠吸收關稅主導的成本波動帶來的營運影響，同時又不損害患者的就醫機會或臨床醫生的信心。

多維度細分揭示患者特徵、治療方式和分佈動態，從而為有針對性的臨床和商業策略提供資訊。

詳細的市場細分能清楚展現臨床偏好、病患行為和分銷動態，進而引導產品開發和推廣策略。針對不同類型的藥物，治療方法方案涵蓋聯合治療、雷射療法、口服療法和局部治療方法等，每種方案都具有獨特的療效、安全性和依從性特徵，這些都會影響臨床醫生的選擇和患者的接受度。治療方法的選擇通常與疾病嚴重程度、合併症負擔以及對快速治療與持續治療的偏好密切相關。

考慮到活性成分的差異，諸如阿莫羅芬、環吡咯烷酮、依芬那唑、Fluconazole、伊曲Itraconazole、他伐硼羅和Terbinafine化合物在作用機制、藥物動力學和安全性方面表現出許多差異。這些差異決定了附加檔、禁忌症和監測要求，並為藥物在臨床上與競爭療法進行定位提供了基礎。劑型也至關重要。乳膏、凝膠、指甲油、溶液和膠囊等劑型會影響患者的用藥體驗，影響患者的依從性，並帶來獨特的生產和監管方面的考量。

我們的分銷管道分析揭示了醫院、線上和零售藥房管道在決定患者獲取藥物、獲得諮詢機會以及銷售點動態方面所發揮的作用。治療場所的細分——居家醫療、住院和門診診所——進一步指導了治療的提供和支持方式，從而影響隨訪、依從性干預和報銷。年齡層（18-65歲、65歲以上和18歲以上）與性別組（女性和男性）相互交織，共同塑造了流行病學趨勢，並解決了特定年齡或性別的安全問題。最後，疾病嚴重程度分類（輕度至中度、復發性和重度）是治療強度和方案選擇的關鍵促進因素。整合這些細分層級，使相關人員能夠識別目標患者群體，客製化通訊，並優先考慮能夠引起製劑研發者和支付方共鳴的臨床證據。

評估美洲、歐洲、中東和非洲以及亞太地區的監管多樣性、醫療保健融資和通路成熟度如何影響醫療保健的採納和准入動態。

區域動態對塑造臨床實踐模式、監管通路和分銷基礎設施至關重要，進而影響產品的普及。在美洲，成熟的臨床網路、廣泛的門診病人服務以及活躍的藥房管道，為創新局部用藥和全身用藥在可靠的安全性和療效比較證據支持下快速獲得臨床應用創造了有利環境。日益關注價值和真實世界結果的報銷結構和支付方審查，正在影響製劑選擇和合約簽訂方式。

歐洲、中東和非洲地區法律規範和醫療保健資金籌措模式的差異，意味著不同地區的市場准入和推廣路徑存在顯著差異。集中式監管管道與區域性報銷談判並存，使得制定量身定做的上市策略和區域證據包裝成為必要。該地區的經銷模式也各不相同，有的市場以醫院為中心進行採購，有的市場則擁有蓬勃發展的零售和線上藥局生態系統，這些都會影響通路的優先排序。

亞太地區擁有龐大的患者群體、不斷發展的臨床指南以及快速現代化的醫療基礎設施。在地化生產能力、某些市場的監管便利管道以及遠端保健的日益普及，都會影響治療方法的評估和應用。在不同地區，人們對皮膚病的文化認知、獲得專科醫生服務的途徑以及藥房管道的成熟度，都會影響患者的參與度、診斷的及時性以及長期治療方案。了解這些區域差異對於協調臨床開發、監管申報和商業推廣至關重要。

成熟企業和新興參與企業在臨床差異化、製劑領先地位、策略聯盟和供應鏈韌性方面的競爭定位

在甲癬治療領域，主要企業企業與新興企業企業之間的動態主要圍繞著臨床差異化、製劑創新以及在真實世界環境中驗證療效的能力。成熟的藥物研發企業憑藉豐富的臨床試驗經驗、廣泛的監管知識以及與關鍵意見領袖和支付方建立的良好關係，保持著競爭優勢。同時，規模較小的專業公司和生技公司正透過針對性地研究製劑科學和開發新型作用機制，開啟新的市場定位。

策略活動包括重點研發投入，用於開發滲透增強劑和組合方案；與輔助性治療器械製造商開展合作；以及建立聯盟，以促進患者獲得專科藥房和數位依從性工具。許可協議和區域分銷夥伴關係是擴大地域覆蓋範圍並最大限度減少直接基礎設施投資的常用途徑。此外，各公司還優先考慮產生患者報告結局和衛生經濟學證據，以支持報銷談判並在競爭激烈的治療層級中脫穎而出。

營運準備，包括生產規模化能力、品管和供應鏈韌性，仍然是一項關鍵的競爭優勢，尤其是在企業面臨關稅和採購方面的挑戰時。那些將臨床差異化與強大的商業化模式和快速分銷策略相結合的企業，將贏得臨床醫生的信任和支付方的認可，並能隨著證據和監管環境的變化靈活調整自身定位。

為製造商和相關人員提供切實可行的策略性舉措，以協調證據產生、配方改進和供應鏈韌性，從而實現永續的競爭優勢。

產業領導者應優先考慮將臨床證據產生、製劑創新和供應鏈應急計畫結合的方法。儘早投資於頭對頭研究和真實世界研究，以了解療效的持久性、老年患者的安全性以及患者報告的結局，將有助於增強與支付方談判和臨床醫生溝通時的價值提案。同時，最佳化製劑以縮短療程並提高藥物對指甲的滲透性，可以顯著提高患者的依從性和滿意度，從而建立一個引人注目的商業性故事。

在營運方面，多元化籌資策略、探索近岸生產方案以及與供應商協商關稅減免條款，將有助於降低貿易波動風險，並保障供應穩定。銷售團隊還需要製定針對不同管道的策略，充分考慮醫院、線上和零售藥房營運的細微差別，同時確保將患者援助計劃和數位依從性工具整合到產品上市計劃中。

最後，企業領導者應尋求與醫療器材創新者、數位醫療服務提供者和區域經銷商建立選擇性夥伴關係，以加速產品在重點市場的進入。這些措施的結合——包括以實證醫學為導向的臨床項目、差異化配方、靈活的採購管道和策略聯盟——可以幫助企業獲得臨床信譽，應對成本壓力，並提供在競爭激烈的治療領域脫穎而出的以患者為中心的解決方案。

嚴謹的混合方法研究設計，結合了相關人員訪談、系統文獻綜述和三角驗證，在明確的約束條件下，提供了可操作的臨床和商業性見解。

研究途徑結合了對皮膚科臨床醫生、藥劑師、供應鏈管理人員和支付方代表的系統性一手調查，以及對監管申報文件、臨床試驗註冊資訊和同行評審文獻的廣泛二次分析。一手調查優先採用半結構式訪談，以捕捉有關治療決策促進因素、未滿足的臨床需求和營運挑戰的細緻觀點，從而能夠與已發表的臨床證據和政策文件進行定性三角驗證。

二次研究包括對已發表的臨床試驗、安全性報告和製劑研究進行系統性回顧，以檢驗作用機制和比較耐受性。數據綜合著重於證據品質、方法透明度和與臨床實踐的相關性。採用三角測量法來協調相關人員之間的分歧，並確定共識領域和需要進一步研究的證據缺口。

品質保證措施包括對資料提取進行獨立審查、採用標準化訪談通訊協定以減少偏倚，以及記錄局限性，例如臨床實踐中的區域異質性和長期結局報告的差異。調查方法旨在突出可操作的見解，同時識別需要額外收集原始資料或進行縱向觀察性研究以提高某些臨床和經濟結論可靠性的領域。

臨床創新、供應鏈韌性與實證商業化對甲癬治療持續進展的策略意義摘要

總之，甲癬是一個臨床需求極高的領域，活性成分、製劑技術和綜合治療方法的進步正在重塑治療選擇。為了取得成功，相關人員必須應對複雜的臨床療效、老年人和併發症族群的安全性考量、不斷變化的銷售管道以及區域監管差異等諸多挑戰。策略性地強調能夠證明療效持久、以患者為中心的便利性和明確的經濟價值的證據，對於確保臨床醫生採納和支付方支持至關重要。

隨著地緣政治和貿易因素的不斷演變，營運韌性，尤其是在供應鏈採購和關稅規避方面，將影響產品的可及性和商業性穩健性。那些將臨床差異化與切實可行的商業化計劃、有針對性的區域策略以及有助於提升市場准入的夥伴關係關係相結合的公司，將更有利於滿足未被滿足的醫療需求，並建立持久的治療產品線。持續投資於真實世界證據和患者參與，對於將創新轉化為實際改善患者照護至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 雷射治療甲癬的普及率不斷提高，療效更佳，復發率更低。
  • 擴大使用添加了多靶點奈米顆粒載體的局部抗真菌指甲油，以增強其滲透性和療效。
  • 為了解決患者依從性問題，人們對安全性更高、療程更短的口服抗真菌藥物越來越感興趣。
  • 遠距皮膚病學平台整合實現了甲癬的遠距離診斷和治療，擴大了患者獲得專科醫生服務的途徑。
  • 基於真菌病原體譜分析，開發基因表現以預測甲癬治療反應並實現個人化治療

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

灰指甲治療市場

  • 聯合治療
  • 雷射治療
  • 口服療法
  • 局部治療

灰指甲治療市場

  • 阿莫羅芬
  • 環吡羅
  • 依芬那康唑
  • Fluconazole
  • Itraconazole
  • 塔瓦博羅勒
  • Terbinafine

第10章 以劑型分類的灰指甲治療市場

  • 奶油
  • 凝膠
  • 指甲油
  • 解決方案
  • 片劑 膠囊

灰指甲治療市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

灰指甲治療市場

  • 居家醫療
  • 住院病人
  • 門診治療

灰指甲治療市場

  • 18至65歲
  • 65歲或以上
  • 未滿18歲

第14章灰指甲治療市場：性別

  • 女士
  • 男性

灰指甲治療市場：依疾病嚴重程度分類

  • 輕度至中度
  • 復發
  • 嚴重

灰指甲治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

灰指甲治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

灰指甲治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭情勢

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis AG
    • Pfizer Inc.
    • Bausch Health Companies Inc.
    • Bayer AG
    • Sanofi SA
    • Galderma SA
    • Johnson & Johnson Services, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • LEO Pharma A/S
Product Code: MRR-FD3F12D54166

The Onychomycosis Treatment Market is projected to grow by USD 4.30 billion at a CAGR of 9.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.09 billion
Estimated Year [2025] USD 2.29 billion
Forecast Year [2032] USD 4.30 billion
CAGR (%) 9.40%

Framing the modern clinical and commercial landscape of onychomycosis to illuminate unmet needs, stakeholder dynamics, and evolving treatment pathways

Onychomycosis presents a persistent clinical and commercial challenge driven by aging populations, increasing comorbidity prevalence, and evolving patient expectations for tolerability and convenience. Clinicians face diagnostic complexity due to atypical presentations and mixed etiologies, while patients often delay seeking care because of perceived cosmetic concerns and previous treatment failures, creating a landscape where unmet needs remain pronounced.

Recent advances in therapeutic modalities, including more targeted topical antifungals, innovations in oral agents, and adjunctive technologies like laser interventions, have diversified the care pathway and expanded options for different patient profiles. Nevertheless, gaps persist in adherence, long-term relapse prevention, and real-world effectiveness data. Payers and providers are converging on value-driven decision criteria, emphasizing safety profiles, treatment duration, and demonstrable improvements in patient-reported outcomes.

This introduction synthesizes the clinical context, stakeholder dynamics, and the shifting treatment paradigm while setting the stage for deeper exploration of regulatory, economic, and commercial forces that shape product development, market access strategies, and competitive positioning in onychomycosis care.

How therapeutic innovation, formulation advances, and care delivery evolution are redefining treatment choice, adherence, and commercialization in onychomycosis care

The onychomycosis landscape is undergoing transformative shifts as therapeutic innovation intersects with changing patient expectations and delivery models. Treatment approaches are moving beyond single-modality prescriptions toward integrated regimens that combine topical agents, oral therapies, device-based interventions, and supportive measures to improve efficacy and adherence. This multidimensional strategy reframes how clinicians select treatments for mild versus severe disease and how manufacturers position product benefits in clinical messaging.

Simultaneously, investment in formulation science has elevated the role of penetration enhancers, novel vehicle systems, and application convenience, which together address long-standing barriers such as slow nail penetration and prolonged treatment durations. Emerging active ingredients and combination strategies are being tested to reduce relapse rates and improve cure durability, while safety and drug-drug interaction profiles remain central to adoption in populations with polypharmacy, particularly older adults.

On the delivery front, digital channels and telehealth services are reshaping patient access and follow-up, enabling earlier intervention and improved adherence monitoring. Pharmacy models are adapting to this shift, with online pharmacies and home care pathways gaining traction alongside traditional hospital and retail channels. These transformative trends create both opportunities for differentiated clinical value and challenges for market entry, necessitating integrated commercialization plans that account for regulatory nuance, payer expectations, and patient-centric positioning.

Assessing the supply chain, sourcing, and procurement consequences of United States tariff measures through 2025 that are reshaping cost structures and commercialization choices

The introduction of new tariff measures in the United States through 2025 has created a ripple effect across supply chains, procurement strategies, and pricing dynamics for dermatology and antifungal products. Manufacturers that source active pharmaceutical ingredients, excipients, or finished goods internationally are reassessing sourcing footprints and contractual terms to mitigate import duties and customs-related timeline risks. These adjustments often translate into supply planning changes that can affect product availability and inventory buffers at distribution points.

Short-term responses have included shifting component sourcing to domestic or low-tariff jurisdictions, renegotiating supplier agreements to include tariff-sharing clauses, and selectively increasing onshore inventory for critical SKUs. Over time, firms are evaluating nearshore manufacturing and localized formulation facilities as structural responses to tariff-driven cost pressures. These strategic investments reduce exposure to trade volatility but require capital allocation decisions that influence product launch timetables and margin structures.

Payers and procurement teams are also reacting by tightening contracting terms, emphasizing value-based arrangements, and scrutinizing total cost of therapy. Clinical leaders and purchasing departments may favor therapeutics with differentiated safety or adherence advantages that justify adjusted pricing in light of increased supply costs. The net effect is a heightened premium on supply chain resilience, commercial flexibility, and the capacity to communicate clear value propositions that absorb the operational impacts of tariff-driven cost changes without undermining access or clinician trust.

Illuminating patient profiles, therapeutic formats, and distribution dynamics through multi-dimensional segmentation to inform targeted clinical and commercial strategies

Detailed segmentation reveals the contours of clinical preference, patient behavior, and distribution dynamics that inform product development and go-to-market strategies. Across drug type, the therapeutic mix ranges from combination therapy and laser therapy to oral therapy and topical therapy, with each modality carrying distinct efficacy, safety, and adherence profiles that influence clinician selection and patient acceptance. Treatment choice often correlates with disease severity, comorbidity burden, and the desire for rapid versus sustained outcomes.

Considering active ingredient differentiation, compounds such as amorolfine, ciclopirox, efinaconazole, fluconazole, itraconazole, tavaborole, and terbinafine exhibit varied mechanisms of action, pharmacokinetics, and safety considerations. These differences dictate labeling, contraindications, and monitoring needs, and they provide the basis for clinical positioning against competing therapies. Formulation matters as well: cream, gel, nail lacquer, solution, and tablet capsule formats change the patient experience, affect adherence, and present unique manufacturing and regulatory considerations.

Distribution channel analysis highlights the role of hospital pharmacy, online pharmacy, and retail pharmacy pathways in determining access, counseling opportunities, and point-of-sale dynamics. Treatment setting segmentation across home care, hospital inpatient, and outpatient clinic environments further guides how therapies are administered and supported, with implications for follow-up, adherence interventions, and reimbursement. Age group distinctions-18 to 65 years, above 65 years, and below 18 years-intersect with gender segments of female and male patients to shape epidemiologic trends and address age- or gender-specific safety concerns. Finally, disease severity categories of mild to moderate, recurrent, and severe act as primary drivers of therapeutic intensity and regimen selection. Synthesizing these segmentation layers allows stakeholders to identify target patient cohorts, tailor messaging, and prioritize clinical evidence generation that resonates with prescribers and payers alike.

Evaluating how regional regulatory diversity, healthcare financing, and channel maturity across the Americas, EMEA, and Asia-Pacific shape adoption and access dynamics

Regional dynamics are pivotal in shaping clinical practice patterns, regulatory pathways, and distribution infrastructures that affect product adoption. In the Americas, established clinical networks, broad outpatient access, and active pharmacy channels create an environment where both innovative topical formulations and systemic therapies can achieve rapid clinical uptake when supported by robust safety and comparative-effectiveness evidence. Reimbursement mechanisms and payer scrutiny tend to emphasize value and real-world outcomes, influencing formulary decisions and contracting approaches.

In Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous healthcare financing models mean that market entry and adoption trajectories vary significantly across jurisdictions. Centralized regulatory pathways coexist with localized reimbursement negotiations, requiring tailored launch strategies and region-specific evidence packages. Distribution models in this region range from hospital-centric procurement in some markets to thriving retail and online pharmacy ecosystems in others, affecting channel prioritization.

The Asia-Pacific region is characterized by a mix of high-volume patient populations, evolving clinical guidelines, and rapidly modernizing healthcare infrastructures. Local manufacturing capabilities, regulatory acceleration pathways in select markets, and growing telehealth penetration influence how therapies are evaluated and adopted. Across regions, cultural perceptions of dermatologic conditions, access to specialist care, and the maturity of pharmacy channels collectively determine patient engagement, diagnostic timeliness, and long-term management approaches. Understanding these regional nuances is essential for calibrating clinical development, regulatory submissions, and commercial deployment.

Competitive positioning driven by clinical differentiation, formulation leadership, strategic alliances, and supply chain resilience among established and emerging players

Competitive dynamics among leading and emerging companies in onychomycosis are centered on clinical differentiation, formulation innovation, and the ability to demonstrate durable outcomes in real-world settings. Established pharmaceutical developers maintain advantages through broad clinical trial experience, extensive regulatory knowledge, and existing relationships with key opinion leaders and payer bodies. At the same time, smaller specialty firms and biotech entrants are leveraging targeted approaches to formulation science and novel mechanisms of action to carve niche positions.

Strategic activity includes focused R&D investment in penetration enhancers and combination regimens, alliances with device manufacturers for adjunctive therapies, and partnerships that accelerate access to specialty pharmacy and digital adherence tools. Licensing agreements and regional distribution partnerships are common maneuvers to extend geographic reach while minimizing direct infrastructure investment. Additionally, companies are prioritizing the generation of patient-reported outcomes and health-economic evidence to support reimbursement discussions and to differentiate in crowded therapy classes.

Operational readiness-manufacturing scalability, quality control, and supply chain resilience-remains a critical competitive lever, especially as firms navigate tariff and procurement headwinds. Companies that integrate clinical differentiation with robust commercialization models and responsive distribution strategies are positioned to secure clinician trust and payer support, while maintaining flexibility to pivot as evidence or regulatory landscapes evolve.

Practical strategic initiatives for manufacturers and stakeholders to align evidence generation, formulation advances, and supply chain resilience for sustained competitive advantage

Industry leaders should prioritize a coordinated approach that aligns clinical evidence generation, formulation innovation, and supply chain contingency planning. Early investments in head-to-head and real-world studies that capture durability of response, safety in older adults, and patient-reported outcomes will strengthen value propositions during payer negotiations and clinician engagement. Concurrently, optimizing formulations to reduce treatment duration and enhance nail penetration can materially improve adherence and patient satisfaction, creating a compelling commercial narrative.

On the operational front, diversifying sourcing strategies, exploring nearshore manufacturing options, and implementing tariff-mitigation clauses with suppliers will reduce exposure to trade volatility and support stable supply. Commercial teams must also cultivate channel-specific strategies that reflect the nuances of hospital pharmacy, online pharmacy, and retail pharmacy operations, while ensuring that patient support programs and digital adherence tools are integrated into launch plans.

Finally, leaders should pursue selective partnerships with device innovators, digital health providers, and regional distributors to accelerate access in priority markets. These combined actions-evidence-focused clinical programs, formulation differentiation, resilient sourcing, and strategic alliances-will enable organizations to capture clinical credibility, manage cost pressures, and deliver patient-centered solutions that stand out in a competitive therapeutic area.

A rigorous mixed-methods research design combining stakeholder interviews, systematic literature review, and triangulation to provide actionable clinical and commercial insights with transparent limitations

The research approach combined structured primary engagement with dermatology clinicians, pharmacists, supply chain managers, and payer representatives alongside extensive secondary analysis of regulatory filings, clinical trial registries, and peer-reviewed literature. Primary research prioritized semi-structured interviews to capture nuanced perspectives on treatment decision drivers, unmet clinical needs, and operational challenges, enabling qualitative triangulation with publicly available clinical evidence and policy documents.

Secondary research involved systematic review of published clinical trials, safety reports, and formulation studies to validate mechanistic claims and comparative tolerability profiles. Data synthesis emphasized evidence quality, methodological transparency, and relevance to real-world clinical practice. Triangulation techniques were applied to reconcile differing stakeholder viewpoints and to identify consensus areas as well as evidence gaps that warrant further study.

Quality assurance measures included independent review of data extraction, standardized interview protocols to reduce bias, and documentation of limitations such as regional heterogeneity in clinical practice and variability in long-term outcome reporting. The methodology was designed to foreground actionable insights while acknowledging areas where additional primary data collection or longer-term observational studies would strengthen confidence in specific clinical or economic conclusions.

Summarizing the strategic implications of clinical innovation, supply chain resilience, and evidence-driven commercialization for sustained progress in onychomycosis care

In conclusion, onychomycosis remains an area of high clinical need where advances in active ingredients, formulation technologies, and integrated treatment approaches are reshaping therapeutic choices. Stakeholders must navigate a complex interplay of clinical efficacy, safety considerations in older and comorbid populations, distribution channel evolution, and regional regulatory diversity to succeed. Strategic emphasis on evidence that demonstrates durable outcomes, patient-centered convenience, and clear economic value will be decisive in securing clinician adoption and payer support.

Operational resilience-particularly in supply chain sourcing and tariff mitigation-will influence product availability and commercial robustness as geopolitical and trade factors continue to evolve. Companies that combine clinical differentiation with pragmatic commercialization plans, targeted regional strategies, and partnerships to enhance access will be best positioned to address unmet needs and build lasting therapeutic franchises. Continued investment in real-world evidence and patient engagement will remain central to translating innovation into meaningful improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of laser-based onychomycosis treatments with improved efficacy and reduced recurrence
  • 5.2. Rising utilization of topical antifungal nail lacquers formulated with multitarget nanoparticle carriers to enhance penetration and efficacy
  • 5.3. Growing interest in oral antifungal agents with improved safety profiles and shorter treatment duration to address patient compliance
  • 5.4. Integration of teledermatology platforms for remote diagnosis and management of onychomycosis to expand patient access to specialists
  • 5.5. Development of gene expression biomarkers to predict treatment response and personalize onychomycosis therapy based on fungal pathogen profiling

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Onychomycosis Treatment Market, by Drug Type

  • 8.1. Combination Therapy
  • 8.2. Laser Therapy
  • 8.3. Oral Therapy
  • 8.4. Topical Therapy

9. Onychomycosis Treatment Market, by Active Ingredient

  • 9.1. Amorolfine
  • 9.2. Ciclopirox
  • 9.3. Efinaconazole
  • 9.4. Fluconazole
  • 9.5. Itraconazole
  • 9.6. Tavaborole
  • 9.7. Terbinafine

10. Onychomycosis Treatment Market, by Formulation

  • 10.1. Cream
  • 10.2. Gel
  • 10.3. Nail Lacquer
  • 10.4. Solution
  • 10.5. Tablet Capsule

11. Onychomycosis Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Onychomycosis Treatment Market, by Treatment Setting

  • 12.1. Home Care
  • 12.2. Hospital Inpatient
  • 12.3. Outpatient Clinic

13. Onychomycosis Treatment Market, by Age Group

  • 13.1. 18 To 65 Years
  • 13.2. Above 65 Years
  • 13.3. Below 18 Years

14. Onychomycosis Treatment Market, by Gender

  • 14.1. Female
  • 14.2. Male

15. Onychomycosis Treatment Market, by Disease Severity

  • 15.1. Mild To Moderate
  • 15.2. Recurrent
  • 15.3. Severe

16. Onychomycosis Treatment Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Onychomycosis Treatment Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Onychomycosis Treatment Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Novartis AG
    • 19.3.2. Pfizer Inc.
    • 19.3.3. Bausch Health Companies Inc.
    • 19.3.4. Bayer AG
    • 19.3.5. Sanofi S.A.
    • 19.3.6. Galderma S.A.
    • 19.3.7. Johnson & Johnson Services, Inc.
    • 19.3.8. Teva Pharmaceutical Industries Ltd.
    • 19.3.9. Viatris Inc.
    • 19.3.10. LEO Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. ONYCHOMYCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. ONYCHOMYCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONYCHOMYCOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 201